VVOS
Vivos Therapeutics, Inc.
Medical - Devices
Market Cap$5M
5Y Perf.-99.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VVOS vs RMTI
Revenue, margins, valuation, and 5-year total return — side by side.
RMTI
Rockwell Medical, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$31M
5Y Perf.-93.0%
VVOS vs RMTI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VVOS | RMTI |
|---|---|---|
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic |
| Market Cap | $5M | $31M |
| Revenue (TTM) | $17M | $17.39B |
| Net Income (TTM) | $-17M | $-1.61B |
| Gross Margin | 55.7% | 16.7% |
| Operating Margin | -91.0% | -8.5% |
| Total Debt | $2M | $12M |
| Cash & Equiv. | $6M | $16M |
VVOS vs RMTI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VVOS
RMTI
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Vivos Therapeutics,… (VVOS) | 100 | 0.4 | -99.6% |
| Rockwell Medical, I… (RMTI) | 100 | 7.0 | -93.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VVOS vs RMTI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VVOS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Rockwell Medical, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
VVOS
Vivos Therapeutics, Inc.
The Income Pick
VVOS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.74
- Rev growth 8.9%, EPS growth 80.1%, 3Y rev CAGR -3.8%
- Lower volatility, beta 0.74, Low D/E 19.0%, current ratio 1.50x
Best for: income & stability and growth exposure
RMTI
Rockwell Medical, Inc.
The Long-Run Compounder
RMTI is the clearest fit if your priority is long-term compounding.
- -99.0% 10Y total return vs VVOS's -99.7%
- -9.3% margin vs VVOS's -98.8%
- -30.3% vs VVOS's -75.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VVOS | 8.9% revenue growth vs RMTI's -31.8% |
| Quality / Margins | RMTI | -9.3% margin vs VVOS's -98.8% |
| Stability / Safety | VVOS | Beta 0.74 vs RMTI's 1.22, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RMTI | -30.3% vs VVOS's -75.7% |
| Efficiency (ROA) | VVOS | -66.7% ROA vs RMTI's -28.6%, ROIC -422.2% vs -11.0% |
VVOS vs RMTI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
VVOS vs RMTI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLVVOSLAGGINGRMTI
RMTIRockwell Medical, Inc.
2leads
VVOSVivos Therapeutics, I…
2leads
6 Total Categories
CATEGORYLEADERvs RMTIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RMTI5/6
Valuation MetricsMultiples, price ratios, and targets
VVOS2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
VVOS6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RMTI6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RMTI leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RMTI is the larger business by revenue, generating $17.4B annually — 1004.0x VVOS's $17M. RMTI is the more profitable business, keeping -9.3% of every revenue dollar as net income compared to VVOS's -98.8%. On growth, RMTI holds the edge at +915.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VVOSVivos Therapeutic… | RMTIRockwell Medical,… |
|---|---|---|
| RevenueTrailing 12 months | $17M | $17.4B |
| EBITDAEarnings before interest/tax | -$15M | -$1.5B |
| Net IncomeAfter-tax profit | -$17M | -$1.6B |
| Free Cash FlowCash after capex | -$14M | $2M |
| Gross MarginGross profit ÷ Revenue | +55.7% | +16.7% |
| Operating MarginEBIT ÷ Revenue | -91.0% | -8.5% |
| Net MarginNet income ÷ Revenue | -98.8% | -9.3% |
| FCF MarginFCF ÷ Revenue | -83.4% | +0.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +75.7% | +915.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.5% | +9.9% |
RMTI leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
VVOS leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | VVOSVivos Therapeutic… | RMTIRockwell Medical,… |
|---|---|---|
| Market CapShares × price | $5M | $31M |
| Enterprise ValueMkt cap + debt − cash | $737,900 | $28M |
| Trailing P/EPrice ÷ TTM EPS | -0.30x | -5.21x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.36x | 0.44x |
| Price / BookPrice ÷ Book value/share | 0.42x | 0.76x |
| Price / FCFMarket cap ÷ FCF | — | — |
VVOS leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
VVOS leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
VVOS delivers a -6.8% return on equity — every $100 of shareholder capital generates $-7 in annual profit, vs $-46 for RMTI. VVOS carries lower financial leverage with a 0.19x debt-to-equity ratio, signaling a more conservative balance sheet compared to RMTI's 0.34x. On the Piotroski fundamental quality scale (0–9), VVOS scores 4/9 vs RMTI's 3/9, reflecting mixed financial health.
| Metric | VVOSVivos Therapeutic… | RMTIRockwell Medical,… |
|---|---|---|
| ROE (TTM)Return on equity | -6.8% | -45.9% |
| ROA (TTM)Return on assets | -66.7% | -28.6% |
| ROICReturn on invested capital | -4.2% | -11.0% |
| ROCEReturn on capital employed | -162.5% | -10.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.19x | 0.34x |
| Net DebtTotal debt minus cash | -$5M | -$3M |
| Cash & Equiv.Liquid assets | $6M | $16M |
| Total DebtShort + long-term debt | $2M | $12M |
| Interest CoverageEBIT ÷ Interest expense | — | -0.01x |
VVOS leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RMTI leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RMTI five years ago would be worth $763 today (with dividends reinvested), compared to $39 for VVOS. Over the past 12 months, RMTI leads with a -30.3% total return vs VVOS's -75.7%. The 3-year compound annual growth rate (CAGR) favors RMTI at -35.2% vs VVOS's -56.9% — a key indicator of consistent wealth creation.
| Metric | VVOSVivos Therapeutic… | RMTIRockwell Medical,… |
|---|---|---|
| YTD ReturnYear-to-date | -73.8% | -9.2% |
| 1-Year ReturnPast 12 months | -75.7% | -30.3% |
| 3-Year ReturnCumulative with dividends | -92.0% | -72.8% |
| 5-Year ReturnCumulative with dividends | -99.6% | -92.4% |
| 10-Year ReturnCumulative with dividends | -99.7% | -99.0% |
| CAGR (3Y)Annualised 3-year return | -56.9% | -35.2% |
RMTI leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VVOS and RMTI each lead in 1 of 2 comparable metrics.
Risk & Volatility
VVOS is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than RMTI's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RMTI currently trades 37.2% from its 52-week high vs VVOS's 8.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VVOSVivos Therapeutic… | RMTIRockwell Medical,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 1.22x |
| 52-Week HighHighest price in past year | $7.95 | $2.10 |
| 52-Week LowLowest price in past year | $0.65 | $0.74 |
| % of 52W HighCurrent price vs 52-week peak | +8.3% | +37.2% |
| RSI (14)Momentum oscillator 0–100 | 30.4 | 35.7 |
| Avg Volume (50D)Average daily shares traded | 230K | 259K |
Evenly matched — VVOS and RMTI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | VVOSVivos Therapeutic… | RMTIRockwell Medical,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RMTI leads in 2 of 6 categories (Income & Cash Flow, Total Returns). VVOS leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallVivos Therapeutics, Inc. (VVOS)Leads 2 of 6 categories
Loading custom metrics...
VVOS vs RMTI: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VVOS or RMTI a better buy right now?
For growth investors, Vivos Therapeutics, Inc.
(VVOS) is the stronger pick with 8. 9% revenue growth year-over-year, versus -31. 8% for Rockwell Medical, Inc. (RMTI). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VVOS or RMTI?
Over the past 5 years, Rockwell Medical, Inc.
(RMTI) delivered a total return of -92. 4%, compared to -99. 6% for Vivos Therapeutics, Inc. (VVOS). Over 10 years, the gap is even starker: RMTI returned -99. 0% versus VVOS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VVOS or RMTI?
By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.
(VVOS) is the lower-risk stock at 0. 74β versus Rockwell Medical, Inc. 's 1. 22β — meaning RMTI is approximately 65% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Vivos Therapeutics, Inc. (VVOS) carries a lower debt/equity ratio of 19% versus 34% for Rockwell Medical, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — VVOS or RMTI?
By revenue growth (latest reported year), Vivos Therapeutics, Inc.
(VVOS) is pulling ahead at 8. 9% versus -31. 8% for Rockwell Medical, Inc. (RMTI). On earnings-per-share growth, the picture is similar: Vivos Therapeutics, Inc. grew EPS 80. 1% year-over-year, compared to -495. 2% for Rockwell Medical, Inc.. Over a 3-year CAGR, RMTI leads at -1. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VVOS or RMTI?
Rockwell Medical, Inc.
(RMTI) is the more profitable company, earning -7. 7% net margin versus -74. 1% for Vivos Therapeutics, Inc. — meaning it keeps -7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMTI leads at -6. 8% versus -74. 3% for VVOS. At the gross margin level — before operating expenses — VVOS leads at 60. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VVOS or RMTI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VVOS or RMTI better for a retirement portfolio?
For long-horizon retirement investors, Vivos Therapeutics, Inc.
(VVOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74)). Both have compounded well over 10 years (VVOS: -99. 7%, RMTI: -99. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VVOS and RMTI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(VVOS: 75.7% · RMTI: 91557.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.